Description: DAXXIFY® is the first new botulinum toxin for cervical dystonica in over 10 years, featuring proven long-lasting symptom relief injection to injection.
Now FDA approved for cervical dystonia DAXXIFY ® is the first new botulinum toxin to be approved for cervical dystonia in adults in over 10 years, featuring proven, long-lasting symptom relief. *
* Median duration of effect, defined as time from treatment until loss of ≥80% of the peak effect (change from baseline in TWSTRS total score averaged across weeks 4 and 6), was 24 weeks with DAXXIFY ® 125U and 20.3 weeks with DAXXIFY ® 250U. In patients that requested retreatment prior to the loss of ≥80% of peak effect, median efficacy remaining was 45% to 54% in ASPEN-1. Median time to retreatment was between 16 and 17 weeks in ASPEN-1 and cycles 1 and 2 in the ASPEN OLS.
A painful and often debilitating condition